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In the long term, 137Cs is probably the most biologically important agent released in many accidental 
(or malicious) radiation disasters. It can enter the food chain, and be consumed, or, if present in the 
environment (e.g. from fallout), can provide external irradiation over prolonged times. In either case, 
due to the high penetration of the energetic γ rays emitted by 137Cs, the individual will be exposed 
to a low dose rate, uniform, whole body, irradiation. The VADER (VAriable Dose‑rate External 
137Cs irradiatoR) allows modeling these exposures, bypassing many of the problems inherent in 
internal emitter studies. Making use of discarded 137Cs brachytherapy seeds, the VADER can provide 
varying low dose rate irradiations at dose rates of 0.1 to 1.2 Gy/day. The VADER includes a mouse 
“hotel”, designed to allow long term simultaneous residency of up to 15 mice. Two source platters 
containing ~ 250 mCi each of 137Cs brachytherapy seeds are mounted above and below the “hotel” 
and can be moved under computer control to provide constant low dose rate or a varying dose rate 
mimicking 137Cs biokinetics in mouse or man. We present the VADER design and characterization of its 
performance over 18 months of use.
In many large-scale radiation exposure scenarios, 137Cs is often the major source of internal or external radiation 
 exposure1–3. 137Cs is generated in large quantities by fission and is one of the major sources of contamination 
following reactor  accidents3 and in nuclear fallout, for ground burst nuclear  detonations4 (but not for air burst 
 scenarios5). Due to its ubiquity in industrial irradiation systems, it presents a hazard for both malicious and 
accidental release (similar to the Goiânia  accident6).
137Cs is a water-soluble γ emitter with a physical half-life of 30 years. When released, it can readily be depos-
ited on surfaces and enter the food  chain7, 8. Because of its environmental persistence and ease of dispersal, 137Cs 
poses a significant risk to the general public. It is therefore important to develop biological assays for identifying 
individuals exposed to internal or environmental 137Cs. With external exposures, following an improvised nuclear 
device (IND) for example, dose rates may be initially high, depending on the level of shielding and distance from 
the  detonation9, and decrease rapidly with  time10, following the so called 7–10  rule11, which is a consequence of 
the various decay times of the wide range of isotopes released. Typical exposure durations are on the order of 48 h 
to 1 week, depending on the time required for evacuation, and doses of multiple Gy over this period are  possible9.
In the case of internal exposures, dose rates are typically much  lower4 but the persistence may be much 
higher: 137Cs permeates all tissues and is cleared over a period of  months12 (although chelating agents somewhat 
accelerate its  clearance13), accumulating damage to tissues and particularly to the genetic material, which may 
result in delayed disease. Thus, in the event of a large-scale accidental or malicious release of volatile radionu-
clides, resulting in internal or external exposures, there is an important need to develop radiation biodosimetry 
assay(s) and technologies for population-based triage and subsequent dose-dependent medical  management2.
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Over the past decade, we have utilized 137CsCl(aq) injection in mice to study the long-term effects of ingested 
137Cs on  cytogenetic14, 15,  transcriptomic16 and  metabolomic17, 18 endpoints. The difficulty of these studies lies in 
the fact that both the study animals and the resulting biofluids are often radioactive and require dedicated equip-
ment to analyze, making systematic studies difficult and expensive. At this time, only one or two laboratories in 
the US have the appropriate facilities and highly trained personnel that are required for conducting these 137Cs 
injection studies.
As the majority of dose delivered from this type of exposure is due to long range γ  rays19 (Half Value Layer: 
82 mm in  water20), the physical dose distribution will be very similar for internal vs. external 137Cs exposures. 
Thus, it is possible to model internal exposures (e.g. from ingested fallout) using an external isotope source, 
provided it is properly modulated to model  biokinetics21.
We have developed the VADER (VAriable Dose-rate External 137Cs irradiatoR) to facilitate modeling of low 
dose rate 137Cs exposures either from ingested or fallout exposures. Our aim was to allow arbitrary dose time 
profile exposures (mimicking biokinetic  clearing12, the 7:10  rule11, constant prolonged dose rate, etc.) to 15 
mice at a time, without generating radioactively contaminated biofluids. As such we believe the VADER to be 
a useful tool for the radiation research community in investigating the effects of prolonged, low dose rate, low 
LET irradiations.
The VADER irradiator is based on “repurposing” of old 137Cs brachytherapy seeds. These seeds were much 
used starting in the 1980s to treat cervical cancer at low dose  rate22, but are no longer in use clinically and so the 
seeds are kept in long-term storage, making them available for research use. At Columbia University, we had 
available a few dozen such sources, ranging from 3 to 35 mCi each. We describe below the construction and first 
two years of operation of the VADER system, including several 30-day mouse irradiations, designed to mimic 
the internal exposure experiments described  in15–18.
VADER design
Overview. The VADER system (shown in Fig. 1a) was designed around the requirement to house 15 mice 
at a time in an environment with dose rates of up to approximately 1 Gy/day over a period of several weeks. The 
VADER geometry was therefore dictated by a balance between the size of the mouse “hotel”, which should be as 
large as possible to accommodate as many mice as possible, and the requirement to provide the required dose 
rate uniformly over its area, using available sources. Within the hotel, mice are free to move around, eat and 
drink ad libitum. Temperature, humidity, airflow and lighting are fully controlled to the required animal care 
standards (20–25 °C; 30–70% humidity). Shielding is provided by a mixture of lead and high-density concrete 
bricks as described below.
Approximately 0.5 Ci of 137Cs brachytherapy seeds, divided between two platters (above and below the mouse 
“hotel”), can be moved from almost touching the mouse “hotel” to about 60 cm above and below it, allowing 
a time-variable dose rate to be implemented. Arrangement of the sources within the platter was optimized to 
achieve as uniform as possible a radiation field at about 1 Gy/day.
A feature of the VADER is that there are no fixed active components within the VADER enclosure. All envi-
ronmental controls and monitoring are integrated into the removable mouse “hotel” so that they can be easily 
replaced in case of radiation damage. This is significantly cheaper and easier than using radiation hardened 
sensors and electronics. Similarly, the motors driving the source holders are placed outside the shielding and 
the platters are moved using steel cables and pulleys.
Figure 1.  (a) Photo of the VADER structure before installation of the shielding. (b) schematic of the VADER 
room layout.
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Design of the mouse “hotel”. A custom mouse “hotel” (Fig. 2) was designed with the goal of housing up 
to 15 mice for 5–7 days at a time (with longer residencies requiring periodic cleaning and replenishment of food 
and water). The “hotel” therefore consists of a 35 cm × 35 cm × 12 cm acrylic box in which the mice are free to 
move and interact with each other. Mice are able to eat and drink ad libitum from four all-plastic, custom-made 
water bottles and reservoirs holding feed pellets placed behind glass rods. Sufficient bedding material is also pro-
vided within the mouse “hotel”. Real time monitoring of the mice is performed using a 180° fisheye USB camera 
(ELP, Amazon) embedded into one of the “hotel” walls.
Four mouse “hotels” were built: two to be used simultaneously (one inside the VADER, and one for the zero 
dose control mice) and two spares to allow the weekly rapid transfer of the mice into a clean “hotel” with fresh 
bedding and replenished food and water.
To monitor the environment in the mouse “hotel”, a temperature/humidity sensor (HWg HTemp, TruePath 
Technologies Victor, NY) is integrated into one of the “hotel” walls. Medical grade air is piped into the “hotel” 
at a rate of 1.5 L/min (10 volume changes/h). Used air is vented into the VADER enclosure through two 100 cm2 
HEPA filters (M-Bar Filter, Allentown Inc, Allentown, NJ). A day-night light cycle is maintained by integrating 
Warm White (3100 K) LEDs (SMD3528; LEDWholesalers, Hayward, CA) into the “hotel” walls. The LEDs are 
powered using an adjustable benchtop power supply (Laskar Electronics, Erie, PA), plugged into a Tork timer 
(Grainger, Lake Forest, IL). The timer was set to “on” between 8 AM and 8 PM and “off ” between 8 PM and 8 
AM. Light intensity was adjusted to 60 lx.
Design of the irradiation system. When designing the source arrangement, our goal was to achieve a 
maximal dose of 1 Gy/day (we can provide higher dose rates using a highly filtered X-ray  machine23) with a 
uniformity of ± 10% or better across the mouse “hotel”. As the VADER system is based on repurposing of exist-
ing 137Cs brachytherapy seeds, we were limited to use available sources, which vary in age, intensity and physical 
dimensions: The seeds available to us ranged between 3 and 35 mCi, as verified using a well counter (HDR 1000 
plus, Standard Imaging Inc, Middleton, WI), and were either 20.0 or 21.0 mm long and between 3.1 and 3.2 mm 
in diameter.
To model various source geometries and select the seed intensities and positions, we calculated the expected 
dose across the mouse “hotel” using a MATLAB script. We modeled each seed as two point sources 7 mm apart. 
The dose rate at a distance R from each half seed is given by
where 67.92 is the dose rate in Gy/day, 1 mm away from a 1 mCi 137Cs point source, obtained using the RadPro 
Calculator (https ://www.radpr ocalc ulato r.com/Gamma .aspx) and a quality factor of 1.
The ideal source placement above and below the mouse “hotel”, within the geometric and source availability 
constraints is shown in Fig. 3. Eight sets of three 20 mm long seeds, totaling about 50 mCi per set were placed 
above/below the four corners of the mouse “hotel” and single 21 mm long 10–17 mCi seeds at the centers of the 
edges and at the center of the “hotel”. Using this geometry, the dose rate within the mouse “hotel” was calculated 
to be uniform to within 20% at the highest nominal dose rate (1 Gy/day), as seen in Fig. 3b.
Custom aluminum platters (Protolabs, Maple Plain, MN; Fig. 4) were designed to hold the seeds. Each platter 
consists of two 27.8 cm wide square aluminum frames (4.75 mm and 3.2 mm thick) with pockets hollowed out 
for the seeds. Openings were made on both frames so that, while the seeds are captive, between the two frames, 
there is no material between the active portion of the seed and the mouse “hotel”, regardless of platter orientation.
The seeds were arranged such that three 20 mm long seeds are placed at the corners, and one 21 mm long 
seed is placed at the center of each edge and at the platter center. Grouping seeds by size in this way simplified 
the design and allowed tighter tolerances on the pocket lengths, preventing the seeds from shifting or falling 
out during use.
The seeds were loaded into the platters using remote manipulators at Columbia University’s David A. Gard-
ner PET Imaging Research Center. Once the seeds were loaded into the platter and the platter lid connected, 
the platters were loaded into a lead safe (MarShield, Burlington, ON) and transported to the VADER location. 
(1)Dose rate
[
Gy/day
]
= 67.92
1
2
Seed activity[mCi]
R[mm]2
Figure 2.  (a) design drawing (front view) of the mouse “hotel”. Air inlet and outlet, feeders, illumination, 
temperature/humidity sensor and camera are indicated. (b) side view photo (taken from the right of panel a). (c) 
close up of temperature and humidity sensor, photo taken from inside the right side of the “hotel”.
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Figure 3.  (a) The source arrangement used in VADER. (b) MATLAB simulation of the dose rate obtained from 
this arrangement. The dashed line corresponds to the extents of the mouse “hotel”; each contour corresponds to 
a 5% variation in expected dose rate.
Figure 4.  (a) photo of the seed holder plate with seeds loaded at the hot cell. (b) Top view design drawing of 
one of the aluminum frames. (c) Exploded side view cross-section, along the red dotted line in (b), showing 
both frames and one seed.
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Loading the platters into the safe and transferring the platters into the VADER were achieved using a 5′ long 
rod with a gripper, that locks onto notches in the central column of the platter, and supervised by Columbia 
University’s Radiation Safety Office.
Within the VADER, the seed platters sit on a frame that is free to move along a vertical Steel rod, using linear 
ball bearings. Two Motors (AZM46MC-TS10, Oriental Motors USA Corp., Torrance, CA) are mounted outside 
the shielding, above the VADER. Each motor controls a spool of 3/32" ultra-flexible stainless-steel wire rope 
(150 lb capacity, McMaster-Carr, Princeton, NJ) used to raise and lower the source platters.
The stepper motors include an absolute mechanical encoder, allowing repeatable absolute positioning, without 
battery back-up or external sensors. The motors also include an electromagnetic brake, which activates when 
power is removed. This allows the source platter to stay in place (rather than falling) in the case of a power failure. 
A built in 10:1 Taper hobbed gearbox provides a torque of up to 2 Nm and a motion of 0.036°/Pulse (17 cm/
turn). Each motor is independently controlled by an AZD-AD Motor driver (Oriental Motors). The two drivers 
are daisy-chained and controlled by RS485 Modbus.
A second steel cable connects each platter to an external counterweight and allows external verification of 
the source position, independent of the motor encoder. The motor encoders were configured such that they read 
zero (home) at the fully retracted position. This allows for a rapid retraction of the sources using the controller’s 
ZHOME (fast return to home) command.
Shielding design. Minimizing radiation exposure to the operators and other uninvolved personnel is a 
prime concern in the design of 137Cs-based irradiators. Shielding for the VADER was designed to maintain 
radiation doses to occupationally exposed personnel (operators) in the room below 0.1 mGy/wk and 0.02 mGy/
wk to anyone outside the room, in accordance with the guidance of NCRP Report  15124. This also allows non-
irradiated, control, mice to be housed in the same room (Fig. 1b).
The room where VADER is installed is below grade, such that the rear wall is the building’s perimeter foun-
dation wall. Adjacent rooms to the east and west and above are uncontrolled areas and considered occupied by 
uninvolved personnel (i.e., general public). An uncontrolled corridor borders the south side of the room. The 
walls are constructed of normal density concrete, 6ʺ thick; the floor above is 4ʺ of normal concrete.
In consultation with Columbia University’s Radiation Safety Office, we have determined the required shielding 
to be either 3ʺ of lead or 12ʺ of high-density concrete (4.7 g/cm3; HDC). The side walls of VADER were built of 
two layers of 6ʺ × 6ʺ × 12ʺ HDC interlocking bricks (Ultraray Inc, Oakville, ON, seen at the bottom of Fig. 1). 
Half bricks were used to offset the vertical seam every other row, to increase structural stability. An external 
aluminum frame was provided to increase lateral stability of the walls. The front and top faces of the VADER, 
however, required penetrations for inserting/removing the mouse “hotel” as well as for control cables and were 
therefore made of lead, which is much more expensive but can be machined. We used 1.5ʺ × 4ʺ × 12ʺ interlock-
ing lead bricks (Radiation Protection Products Inc. Wayzata, MN), similarly arranged in two layers with half 
bricks used to offset the seams. A custom sliding door made of a 3ʺ thick lead slab, held in an aluminum frame 
was designed and built, to allow access to the mouse “hotel”. Although heavy, the door slides on rails and can 
be easily opened and closed with one hand. The rear face of the irradiator was not shielded as it abuts the north 
wall, is below grade and hence, there are no occupied spaces beyond.
VADER control and monitoring. Control software for the VADER was written in Visual  C++ (Micro-
soft, Redmond, WA). The software consists of a single windows “form” that controls the source movement and 
camera as well as monitoring the temperature and humidity in the mouse “hotel”. The PC running the VADER 
control software was configured to allow for secure remote access to allow monitoring of VADER operations 
from offsite.
As an experiment could last 30 days or more, it is crucial to allow recovery from unforeseen computer reboots 
(e.g. system updates or power failures). The VADER control software was therefore configured to automatically 
start at computer start up (prior to login) and maintain files containing the start time of irradiation and the 
required irradiation profile: a list of required source positions as a function of time. During operation, the control 
software periodically compares the elapsed time since the beginning of the experiment to this list and verifies 
that the positions reported by the motors correspond to the required ones, moving the sources if necessary. The 
motor position and status as well as the temperature and humidity probe values, are displayed on screen and 
saved to a comma separated variable (csv) log file, which can be imported into excel.
Dosimetry
Offline dosimetry of the VADER was performed using an ionization chamber (10 × 6–6, Radcal Corp., Monrovia, 
CA) calibrated to measure Air-Kerma. Following a background measurement outside the VADER the ionization 
chamber and electrometer were placed at the center of the mouse “hotel” and dose integrated for 5 min at each 
retraction position. Annual repeat measurements gave dose rates consistent with the expected 2.3%/year decay 
of the seeds (Fig. 5). The required retraction as a function of dose rate was interpolated by fitting to a third order 
polynomial. When monitoring VADER operations, the nominal dose rate was calculated based on the source 
position and ionization chamber results.
Dose uniformity was evaluated using EBT3 radiochromic film (Ashland Advanced Materials, Bridgewater, 
USA). Four 17.5 cm square pieces of film were taped down at the bottom of the mouse “hotel” and exposed 
for several days. Films were scanned on a 48 Bit RGB Epson Perfection V700 Photo flatbed scanner (Epson, 
Japan), with a resolution of 300 dpi. We used the web application radiochromic.com25 to analyze the films. The 
program used a set of calibration films, obtained by exposing film to known doses of 250 kVp X-rays, to define a 
6
Vol:.(1234567890)
Scientific Reports |        (2020) 10:19899  | https://doi.org/10.1038/s41598-020-76941-2
www.nature.com/scientificreports/
relationship between the optical density of the three colors and a given dose. The two-dimensional dose distribu-
tion for a given film could then be determined using this relationship with high accuracy.
Figure 6 shows the dose uniformity across the surface of the mouse “hotel” at the highest dose rate. Variation 
of measured dose across the film is 10% (standard deviation). Hot spots are evident near the 50 mCi source clus-
ters at the highest dose rates. These average out as the sources retract from the “hotel”; at 1 Gy/day the standard 
deviation across the “hotel” was reduced to 3.5%.
In vivo dosimetry was performed on a mouse-by-mouse basis, by injecting a glass encapsulated TLD chip 
into each  mouse26. After irradiation, the TLD rods were read on a Harshaw 2500 TLD reader (Thermo Fisher 
Scientific), using the recommended heating profile (5 °C/s ramp to 300 °C, hold at 300 °C and cool to 50 °C). 
Dose was reconstructed as described  in26.
Mouse studies
All animal experiments were approved by the Columbia University Institutional Animal Care and Use Commit-
tee (IACUC; approved protocol AAQ2410) and were conducted under all relevant federal and state guidelines.
Before starting any biological study for biodosimetry endpoints, we placed 15 mice into the mouse “hotel” 
and monitored them over 2 weeks. No weight loss and normal food and water consumption was found. Initially, 
the mice were exploratory in the new environment and after about 30 min settled down. Similar behavior was 
observed in the VADER experiments.
Figure 5.  Dose rate as a function of reported motor position, measured using an ionization chamber in 1st tests 
of the VADER (solid symbols), one year later (open symbols) and two years later (half open symbols). We expect 
a 2.3% decay per year due to the half life of 137Cs.
Figure 6.  Field uniformity, as measured using Gafchromic film at the highest dose rate (1.2 Gy/day). The four 
panels correspond to four 17.5 cm square films exposed simultaneously, covering the entire mouse “hotel” area. 
Contours correspond to 0.5 Gy (roughly 5%) steps.
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Mouse handling. For a typical experiment, 30 (15 irradiated and 15 control, randomly assigned) 7 week old 
C57BL/6J “cage mate” mice were purchased from Charles River Laboratories (Frederick, MD) and kept at the 
Columbia University Irving Medical Center animal facility for one week of adaptation. Glass-encapsulated TLD 
rods were injected at 8 weeks of age as described  in26.
Animals were then placed in the VADER, provided with food and water ad libitum and kept on a 12:12 h 
light–dark schedule. For exposures longer than 1 week, the mouse “hotel” was removed from the VADER and 
mice transferred to a clean “hotel” with fresh bedding, food and water every 5–7 days. During this transfer, mice 
were outside the irradiator for a total of 5 min. Control mice were placed in an identical “hotel” in the same room 
and were transferred to a clean “hotel” roughly an hour before the irradiated mice. Temperature and humidity 
were monitored in both “hotels”.
Most experiments performed over the 1st year of operation of the VADER consisted of multiple runs where 
15 mice were placed in the VADER and 3–5 mice removed at each time point. For long (1 month) irradiations, 
the early time points (< 1 week) were performed in one run and the later time points in an independent run 
allowing more mice per time point. More recently, we have used a previously described portable  incubator27 to 
perform 2–3 day irradiations of blood at dose rates of 1 Gy/day. We have also begun more systematic studies 
using mice, irradiated at fixed dose rates of 1 Gy/day.
Cell counts. Peripheral whole blood samples were collected at euthanasia from each mouse by cardiac punc-
ture using a heparin-coated syringe. The spleen was excised and homogenized and the isolated splenocytes were 
suspended in PBS 2% FBS. 20 μl of heparinized blood or spleen suspension was diluted to 200 μl in RBC lysis 
solution, stained with mouse CD45 antibody (WBC marker, clone 30-F11, eBioscience, San Diego, CA) and 
analyzed using flow cytometry (CytoFLEX, Beckman Coulter, Pasedena, CA).
Apoptosis. Peripheral blood cells and splenocytes were fixed using the FIX & PERM Cell Permeabiliza-
tion Kit (Thermo Fisher Scientific, Waltham, MA) and stained with nuclear dye DRAQ5 (Thermo Fisher Sci-
entific, Waltham, MA). The cells were measured using the ImageStreamX Mark II Imaging Flow Cytometer 
(Luminex Corporation, Austin, Texas). Images of 5000 cells per sample were acquired at 40X magnification 
using the 488 nm excitation laser. Captured images were analyzed using IDEAS (Luminex Corporation, Austin, 
Texas) software for measuring proportion of apoptotic cells, as identified by automated image analysis based 
on nuclear imagery features in combination with bright field  morphology28. Data was expressed as mean and 
standard deviation and were analyzed using GraphPad Prism 6.0 (GraphPad Software, San Diego, CA, USA). 
The Kruskal–Wallis test was performed to compare data among all study groups. The Mann–Whitney U test was 
used to compare between two groups. P < 0.05 was considered statistically significant.
One week study. The first VADER experiment focused on system validation. eleven mice were housed 
in the VADER mouse “hotel” (with four controls in a second “hotel”, in the same room). The VADER was pro-
grammed to produce the dose profile show in Fig. 7 and Table 1, mimicking the dose and dose rate kinetics after 
Figure 7.  VADER programming for a 1 week run. The solid curve (left axis) displays the target dose rate as a 
function of time. The dashed curve (right axis) displays the target cumulative dose as a function of time.
Table 1.  Dose rates and doses for the one-week study.
Day Dose rate [Gy/day] Nominal dose [Gy] Average TLD dose [Gy]
1 0.84 0.87 0.66 ± 0.03
4 0.6 3.1 2.5 ± 0.3
7 0.36 4.5 4.33 ± 0.14
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injection of 6.66 MBq 137CsCl(aq)15). Four irradiated and two control mice were sacrificed at 24 h, three irradi-
ated and one control on day 4 and the remaining four irradiated and one control mouse were sacrificed on day 
7. Blood leukocyte and splenocyte cell counts (CD45 + cells) are shown in Fig. 8. As expected, the cell counts 
decreased with increasing absorbed dose over the irradiation period. Due to the large variation in the control 
mice, only the day 7 leukocyte and splenocyte counts were significantly lower than the control (p < 0.05).
The apoptosis frequency in the mouse peripheral blood leukocytes and splenocytes, respectively is shown 
in Fig. 9. Although the overall rate of formation of apoptotic cells was relatively low (< 3%), there was a sig-
nificant (p < 0.05) increase in apoptotic blood leukocytes by day 7 (dose = 4.33 Gy) and in splenocytes by day 4 
(dose = 2.5 Gy) and a further increase by day 7.
One month study. Figure 10 shows the measured dose, dose rate, temperature and humidity during one 
of the 30 day studies. As the VADER mouse “hotel” is limited to a capacity of 15 mice, experiments were run 
separately for the early and late time points. Figure 10 shows a run where time points of 5, 20 and 30 days were 
assessed.
The measured dose rate, reconstructed from source position, was confirmed by the per-mouse TLD dosimetry 
and matched the required dose points. Temperature and humidity were within the accepted parameters. The 
decline in humidity is likely due to removal of 1/3 of the mice on days 5 and 20 (air flow into the mouse “hotel” 
was not humidified).
Figure 11 and Table 2 show the leukocyte counts for this study, which declined similarly to those in Fig. 8a 
with the beginning of recovery evident at Day 20–30.
Discussion
We present here a novel low-dose-rate irradiator based on re-purposed 137Cs brachytherapy seeds. The irradia-
tor was designed to mimic internal or external exposures from high level environmental 137Cs contamination, 
resulting in chronic exposures of Gy-level doses over days to weeks of exposure. Thus, the VADER was designed 
to provide dose rates of 0.1–1 Gy/day. Obtaining a wider range of doses can be achieved by building a taller 
structure, allowing the sources to be retracted further from the mice, but due to the 1/r2 decrease of dose rate the 
Figure 8.  Leukocyte (CD45 +) counts in (a) peripheral blood and (b) spleen, following irradiation using the 
protocol shown in Fig. 7. Symbols correspond to individual mice; the center line and error bars are average and 
Standard deviation. Asterisk denotes p < 0.05 compared to control.
Figure 9.  Fraction of apoptotic cells in (a) peripheral blood and (b) spleen, following irradiation using the 
protocol shown in Fig. 7. Symbols correspond to individual mice; the center line and error bars are average and 
Standard deviation. Asterisk denotes p < 0.05 compared to control.
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system would have to be too tall to fit in a standard room to gain significantly in this respect. Another option, 
for achieving lower dose rates, if required, is to remove some of the seeds or replace them with weaker ones, 
essentially scaling down all doses.
Alternate technologies. The validity of modeling internal 137Cs exposures with external exposures was 
demonstrated by others, using a cabinet type 137Cs irradiator equipped with a computer controlled mercury 
 attenuator29, 30. In that system a mercury reservoir is placed between a large (18 Ci) 137Cs source and a stack of 
mouse cages. The level of mercury in the reservoir is modified, varying the attenuation of γ-rays, achieving dose 
Figure 10.  (a) Dose rate (solid line, right axis) and cumulative dose (dashed line, left axis) calculated from 
source position over a 30-day study. The vertical lines in the dose rate curve correspond to brief VADER 
openings for “hotel” cleaning and removing mice for analysis. Symbols at days 2, 3, 5, 20 and 30 are individual 
TLD readings for 5 mice at each time point (open symbols from a separate 5-day study using the same dose 
profile, conducted immediately prior to the 30-day study). (b) Measured humidity (thick purple line, left axis) 
and temperature (thin blue line, right axis) in one of the “hotels” used for the VADER. The gaps represent times 
when a different “hotel” was in use.
Figure 11.  Leukocyte (CD45 +) counts at various times during a 30-day study. Symbols correspond to 
individual mice; the center line and error bars are average and standard deviation. Single, double and triple 
asterisks denote p < 0.05, p < 0.001 and p < 0.001, compared to control, respectively.
Table 2.  Dose rates and doses for the 30-day study. The TLD average and standard deviation dose based on 5 
mice each. P values are based on an unpaired t test, comparing to controls.
Day Dose rate [Gy/day] Nominal dose [Gy] Average TLD dose [Gy] Leukocyte counts p value
Control 0 0 − 0.05 ± 0.08 2300 ± 800 NA
2 0.82 1.9 1.6 ± 0.1 1100 ± 300 0.005
3 0.72 2.7 2.3 ± 0.1 1000 ± 800 0.007
5 0.59 4.0 3.7 ± 0.1 800 ± 400 0.0004
20 0.14 8.7 8.7 ± 0.2 1100 ± 400 0.003
30 0.10 9.8 9.95 ± 0.2 1300 ± 600 0.002
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rates between approximately  10–4 and 0.25 Gy/h29. This setup has been routinely used for calibration studies for 
internal emitter biomarker  studies31–33.
An alternate approach to attenuation, which is likely to alter the energy spectrum of the source, is to place 
the source very far from the animals to be irradiated. An example of this approach is the NMBU FIGARO low 
dose rate facility in  Norway34. FIGARO utilizes a 60Co source, providing a dose rate between 3 Gy/h, just outside 
the collimator and 0.4 mGy/h, 20 m away. The obvious drawback of such a system is that it requires a very large 
facility, which is not suited to an urban university/medical center. FIGARO to date has not published experi-
ments using variable dose rates, though they could be easily achieved by periodically moving the animal cages. 
As dose rate varies with the distance from the source, care needs to be taken that the animals cannot move too 
much in this direction. This is not a huge problem when irradiating at a source distance of 20 m but becomes 
problematic for higher dose rates that require source distances of 1–2 m.
VADER performance. General. At the time of writing this paper the VADER has been in operation for 
two years including three 30-day studies and thirteen shorter (3–7 day) runs, for the study of cytogenetic, pro-
teomic, transcriptomic, and metabolomic endpoints. In addition to the design and dosimetry validation of the 
VADER we presented here blood count and apoptosis data from one 7-day study and one 30-day study. Addi-
tional manuscripts focusing on these different endpoints will be presented elsewhere (e.g.35). It should be noted 
that in our prior injection-based studies we were not able to access hematological data (especially at earlier time 
points) as the blood was too radioactive to analyze. Use of the VADER obviates this problem.
In the first pilot study (conducted in August 2018) the temperature in the VADER ranged from 26 to 30 °C. 
Temperature in the control “hotel” was slightly lower (23–29 °C), although both were somewhat warmer than the 
recommended temperatures for housing mice. Humidity in both “hotels” ranged from 40 to 60%. Following this 
week-long experiment, a second air conditioning unit was installed in the room, lowering summer temperatures 
to more acceptable levels. No temperature deviations were seen in any of the subsequent experiments.
During this pilot study we also discovered several errors in data logging, which were corrected. One power 
outage had been experienced, but the VADER control software had recovered successfully and resumed opera-
tion when the power was restored.
Dosimetry. An important aspect of performing these long-term studies, where mice are free to roam in a (pos-
sibly) spatially varying radiation field is individualized dosimetry. We have developed an in  vivo dosimetry 
 technique26, based on glass encapsulated TLD rods. The glass encapsulation allows the TLDs to be injected into 
mice without being damaged by the surrounding biofluids, while also allowing readout and annealing in the 
encapsulated state.
Figure 12 demonstrates in vivo measured doses, reconstructed using the TLDs, as a function of the nominal 
(requested) dose. The data show good agreement at the higher doses but the TLD doses were slightly lower than 
nominal at the lower doses. This may be due to the fact that most low doses were delivered in a short time using 
Figure 12.  TLD reconstructed doses (in Gy) for mice irradiated in the VADER. Each point corresponds to 
an individual mouse dose. The dashed line is the identity and the dotted lines are ± 10%. The insert shows a 
photo of the encapsulated TLDs, reproduced  from26, © Institute of Physics and Engineering in Medicine. Photo 
reproduced by permission of IOP Publishing. All rights reserved.
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the highest dose rate setting, where there is considerable spatial variation of dose at dose rates above 1 Gy/day, 
and it is possible that mice spent more time in the lower dose areas.
Preliminary data. The data above represent the first two runs of the VADER. Both runs utilized a dose/
time profile measured in our prior 137Cs injection  studies15–18 tracking mice over 1 week or 1 month. Leukocyte 
depletion kinetics showed a nadir around day 3–7, similar to that seen for acute  exposures36. The results show 
that leukocyte levels have not fully recovered by day 30, as is seen in acute  exposures36. This is likely because the 
animals are continuously irradiated after the nadir. The low dose rate (below 0.3 Gy/day after day 7), results in 
a low rate of cell killing combined with the repopulation, thus delaying the full recovery of leukocyte numbers.
The main goal of the 30 day experiment was to mimic the injected 137Cs experiments reported  previously16, 
indeed, both the pattern of up and down regulated genes and the metabolic profiles seen in that study was repro-
duced in this experiment and two subsequent repeats (manuscripts in preparation).
Conclusions
We describe a low dose irradiation facility based on repurposed 137Cs brachytherapy seeds. The VADER provides 
dose rates between 0.1 and 1.2 Gy/day to up to 15 mice at a time. Environmental conditions suitable for hous-
ing mice are maintained in the VADER for weeks at a time allowing protracted experiments with short weekly 
breaks for “hotel” cleaning and replenishment of food and water.
The system is currently in routine use at Columbia University and can reproduce the results of 137Cs injec-
tion experiments without the complications and costs involved in the handling of radioactive reagents, animals, 
and biofluids.
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